XBIO - Xenetic Biosciences, Inc.
| Previous Close | 2.4600 |
| Open | 2.4200 |
| Bid | 2.2600 x 800 |
| Ask | 2.3100 x 1100 |
| Day's Range | 2.2500 - 2.4800 |
| 52 Week Range | 1.3690 - 8.9500 |
| Volume | 47,078 |
| Avg. Volume | 105,387 |
| Market Cap | 21.328M |
| Beta (3Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1370 |
| Earnings Date | Nov 13, 2017 - Nov 17, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- Simply Wall St.•14 days ago
What Investors Should Know About Xenetic Biosciences Inc’s (NASDAQ:XBIO) Financial Strength
Xenetic Biosciences Inc (NASDAQ:XBIO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is XBIO Read More...
- InvestorPlace•4 months ago
Why Xenetic Biosciences Just Surged 28 Percent
Nanocap stocks are inherently risky in the stock market, but can certainly pay off for speculators when they go up. Xenetic Biosciences Inc. (NASDAQ:XBIO) surged 28%, up twofold from the $2 level the stock has been stuck at over the last year. At a closing price of $4.08 on Monday, Aug. 13, XBIO stock is still well below the $8.95 intraday high set in late-June.
- ACCESSWIRE•4 months ago
Xenetic Biosciences Oncology Phase II Trial in Process, Pipeline Overview
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Xenetic Biosciences, Inc. (XBIO), a clinical-stage biopharmaceutical company. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. In 2018, an estimated 63,000 cases of endometrial cancer will be diagnosed in the U.S., and an estimated 11,000 disease-associated deaths will occur.
- ACCESSWIRE•4 months ago
Today’s Research Reports on Stocks to Watch: Xenetic Biosciences and Antares Pharma
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / There was no news to explain the sudden jump shares of Xenetic Biosciences saw in Monday’s trading session. Shares of Antares Pharma also climbed higher despite any news. It was momentum that kept the stock going after the company announced last week that it would be working with Pfizer.
- ACCESSWIRE•6 months ago
Upcoming FDA Catalyst and Disruptive Drug Candidate Indicate Big Near-Term Upside For This Unknown Healthcare Stock
Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.
- Simply Wall St.•7 months ago
Interested In Xenetic Biosciences Inc (NASDAQ:XBIO)? Here’s How It Performed Recently
Understanding Xenetic Biosciences Inc’s (NASDAQ:XBIO) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...
- Simply Wall St.•10 months ago
How Does Xenetic Biosciences Inc (NASDAQ:XBIO) Affect Your Portfolio Returns?
If you are looking to invest in Xenetic Biosciences Inc’s (NASDAQ:XBIO), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...
- Simply Wall St.•11 months ago
Xenetic Biosciences Inc (NASDAQ:XBIO): Is Now The Time To Bet On Healthcare?
Xenetic Biosciences Inc (NASDAQ:XBIO), a USD$21.71M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...
- Simply Wall St.•11 months ago
Does Xenetic Biosciences Inc’s (NASDAQ:XBIO) CEO Pay Compared Well With Peers?
Jeff Eisenberg took the helm as Xenetic Biosciences Inc’s (NASDAQ:XBIO) CEO and grew market cap to $16.72M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...
